HEALTH TECHNOLOGY ASSESSMENT IN IRELAND

2000 ◽  
Vol 16 (2) ◽  
pp. 449-458 ◽  
Author(s):  
Frank Ahern ◽  
Nessa O'Doherty

Ireland's health system is primarily funded from general taxation and is publicly provided, although private health care retains a considerable role. It is a unique structure, a mixture of universal health service free at the point of consumption and a fee-based private system where individuals subscribe to private health insurance that covers some of their medical expenses. The recent history of the Irish health services saw consolidation of existing services and an expansion into new areas to adapt to changing practices and needs. There has also been a drive to extract maximum efficiency so as to maintain the volume and quality of patient services at a time of very tight financial constraints. Introduction of new health technologies continued to accelerate. New technologies tended to spread rapidly before systematic appraisal of their costs and benefits. When the state is involved in funding the public hospital system, acceptance of new technology is a matter for discussion between agencies and the Department of Health and Children. Decisions about spending annual “development funding” have generally not been based on careful assessment of proposals for new technology. In 1995, a healthcare reform put new Public Health Departments in Health Boards in a prime position in Ireland's health services organization. These departments now emphasize evidence-based medicine. While Ireland does not have a national health technology assessment (HTA) program, there are plans to form an advisory group on HTA in 1998. HTA is seen as a significant element of future health policy in Ireland.

2013 ◽  
Vol 23 (2) ◽  
Author(s):  
Brynjar Fure ◽  
Vigdis Lauvrak ◽  
Helene Arentz-Hansen ◽  
Åse Skår ◽  
Sari Susanna Ormstad ◽  
...  

I Norge har vi siden slutten av 1990-tallet utført metodevurderinger om effekt av tiltak i helsetjenesten som støtte til beslutningstakere. Metodevurderingene ble frem til 2004 utført ved Senter for medisinsk metodevurdering, og deretter ved Nasjonalt kunnskapssenter for helsetjenesten, som i dag er landets nasjonale metodevurderingsorganisasjon. Metodevurderinger kan i prinsippet brukes som beslutningsstøtte på alle nivåer i helsetjenesten, men i praksis benyttes metodevurderinger først og fremst som en del av et kunnskapsbasert beslutningsgrunnlag på overordnet politisk eller administrativt nivå. Hovedhensikten med metodevurderinger er å bidra til at gode og nyttige metoder kommer raskt ut til pasientene. Med metoder menes alle tiltak som er aktuelle i helsetjenesten, både legemidler, medisinsk utstyr, prosedyrerelatert diagnostikk og behandling, screening og organisatoriske tiltak. Metodevurderingene sammenfatter først og fremst kunnskapsgrunnlaget om klinisk effekt og sikkerhet, men ofte inngår også en helseøkonomisk evaluering. Her benyttes en strikt og etterprøvbar metodikk utarbeidet av anerkjente og veletablerte internasjonale metodevurderingsmiljøer. Avhengig av hva slags metode det er snakk om, vurderes også andre aspekter, som for eksempel etiske, sosiale, organisatoriske eller juridiske konsekvenser av å innføre metoden. For å sikre metodevurderingenes relevans i de kliniske miljøene, inviteres vanligvis kliniske spesialister til å delta i arbeidet. Metodevurderingsorganisasjoner samarbeider i økende grad med søsterorganisasjoner i andre land, ikke bare rundt forskning og utvikling av metodikken som benyttes i metodevurderinger, men også ved å dele resultater fra metodevurderinger, og dermed unngå dobbeltarbeid. En metodevurdering oppsummerer utelukkende forskningsresultatene om en metode, og inneholder ingen anbefaling om hvorvidt metoden bør innføres i helsetjenesten. Fure B, Lauvrak V, Arentz-Hansen H, Skår Å, Ormstad SS, Vang VS, Frønsdal KB. Health Technology Assessment: Knowledge-based decision support at the superior level in the health services. Nor J Epidemiol 2013; 23 (2): 165-169. ENGLISH SUMMARY In Norway, Health Technology Assessment (HTA) has existed since the late 1990s as support for decision makers in the health services. Until 2004, HTA was performed at the Norwegian Centre for Health Technology Assessment and later at the Norwegian Knowledge Centre for the Health Services which is, today, the national HTA-organization in Norway. HTA may be used as decision support at all levels in the health services. However, in practice, HTA is mainly used as part of evidence-based decisions by politicians or health leaders. The main purpose of HTA is to contribute to rapid introduction of useful health technologies, for the benefit of the patients. HTA may be used for all types of health technologies, including pharmaceuticals, medical devices, diagnostic and therapeutic procedures, screening and organizational measures. In HTA-reports, the evidence regarding effect and safety of a technology is summarized, and, in most cases, also include a health economic evaluation. A strict and transparent methodology, developed by well-established international HTA-agencies, is used. Other aspects such as ethical, social, organizational or legal consequences of the technology may be evaluated, depending on the technology. In order to make HTA clinically relevant, clinical experts are usually invited to participate in the work. HTA-organizations, increasingly, collaborate with HTA-organizations in other countries, not only in order to develop the methodology of HTA, but also to share the results of HTA-reports, and, thus, avoid double work. An HTA-report summarizes the research results on a technology, and gives no advice regarding the decision that should be made about the introduction of the new technology.


Author(s):  
Amy von Huben ◽  
Martin Howell ◽  
Joseph Carrello ◽  
Sarah Norris ◽  
Sally Wortley ◽  
...  

Abstract Background As health services increasingly make investment decisions in digital health technologies (DHTs), a DHT-specific and comprehensive health technology assessment (HTA) process is crucial in assessing value-for-money. Research in DHTs is ever-increasing, but whether it covers the content required for HTA is unknown. Objectives To summarize current trends in primary research on DHTs that manage chronic disease at home, particularly the coverage of content recommended for DHT-specific and comprehensive HTA. Methods Medline, Embase, Econlit, CINAHL, and The Cochrane Library (1 January 2015 to 20 March 2020) were searched for primary research studies using keywords related to DHT and HTA domains. Studies were assessed for coverage of the most frequently recommended content to be considered in a nine domain DHT-specific HTA previously developed. Results A total of 178 DHT interventions were identified, predominantly randomized controlled trials targeting cardiovascular disease/diabetes in high- to middle-income countries. A coverage assessment of the cardiovascular and diabetes DHT studies (112) revealed less than half covered DHT-specific content in all but the health problem domain. Content common to all technologies but essential for DHTs was covered by more than half the studies in all domains except for the effectiveness and ethical analysis domains. Conclusions Although DHT research is increasing, it is not covering all the content recommended for a DHT-specific and comprehensive HTA. The inability to conduct such an HTA may lead to health services making suboptimal investment decisions. Measures to increase the quality of trial design and reporting are required in DHT primary research.


2000 ◽  
Vol 16 (2) ◽  
pp. 347-381 ◽  
Author(s):  
Torben Jørgensen ◽  
Anne Hvenegaard ◽  
Finn Børlum Kristensen

The Danish healthcare services are mainly provided by public sector institutions. The system is highly decentralized. The state has little direct influence on the provision of healthcare services. State influence is exercised through legislation and budget allocations. The main task of the state is to initiate, co-ordinate, and advise. Counties, which run the hospitals, also decide on the placement of services. The hospital sector is controlled within the framework of legislation and global budgets. General practitioners occupy a central position in the Danish healthcare sector, acting as gatekeepers to the rest of the system. The system works well, and its structure has resulted in steady costs of health care for a long period. There is no regulatory mechanism in the Danish health services requiring use of health technology assessment (HTA) as a basis for policy decisions, planning, or administrative procedures. However, since the late 1970s a number of comprehensive assessments of health technology have formed the basis for national health policy decisions. In 1997, after years of public criticism of the quality of hospital care and health technologies, and on the basis of a previously developed national HTA strategy, a national institute for HTA (DIHTA) was established. There seems to be a growing awareness of evidence-based healthcare among health professionals and a general acceptance of health economic analyses as a basis for health policy decision making. This progress is coupled with growing regional HTA activity in the health services. HTA seems to have a bright future in Denmark.


2019 ◽  
Vol 35 (S1) ◽  
pp. 56-57
Author(s):  
Mírian Cohen ◽  
Ana Flávia Lima ◽  
Sandro Miguel ◽  
Marina Aziz ◽  
Ricardo Bertoglio Cardoso ◽  
...  

IntroductionSince 2007, 23 Núcleos de Avaliação de Tecnologias em Saúde or hospital-based health technology assessment (HB-HTA) units have been established in teaching hospitals across Brazil. These units aim to promote the development of health technology assessment in hospitals, assisting the decision-making process for implementing new technologies and evaluating and promoting the rational use of widespread technologies.MethodsAn online questionnaire was sent by e-mail to all HB-HTA units registered in the Brazilian Network for Evaluation of Health Technologies. Information was acquired to comprehensively assess the activity of the units.ResultsAll 23 HB-HTA units answered the questionnaire. Of these, 65 percent had a technology prioritization process. The technologies assessed included drug therapies (73%), equipment (64%), medical devices (64%), clinical protocols (46%), and emerging technologies (27%). The dimensions of health technology assessment (HTA) evaluated by these organizations were: efficacy (76%); effectiveness (67%); safety (67%); costs (52%); cost effectiveness or cost utility (52%); and budget impact (43%). The hospital departments that required more HTA studies were: cardiology (50%); infectious diseases (45%); hospital management (45%); oncology (40%); surgery (40%); and endocrinology (20%). HTA studies supported: incorporation of new technologies (81%); protocol or guideline development (57%); new indications for already approved technologies (38%); and withdrawal of obsolete technologies (29%). Half of the institutions also conducted educational or training activities. The main difficulties reported were a lack of trained professionals (78%), funding (70%), and material resources (48%).ConclusionsFor low- and middle-income countries, the process of implementing HB-HTA units remains a challenge. Even though human resources and funding are scarce, HB-HTA units continue to develop. Given their importance in the decision-making process, it is imperative that every effort is made to ensure their activities continue.


2007 ◽  
Vol 23 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Henry Z. Borowski ◽  
Jon Brehaut ◽  
David Hailey

Objectives: The objective of this study was to develop and implement a decision-making process for public funding of health services that links policy areas with health technology assessment and input from interested parties.Methods: Health authorities, assessment organizations, and healthcare professionals were consulted as a follow-up to recommendations of an expert panel established by the Alberta government. The methods involved formulation of an eight-stage, collaborative process that incorporates identification through the health ministry of health technologies requiring review, assessment of the technologies using expert groups in Alberta, and consultation and formulation of advice within the ministry to inform ministerial funding decisions.Results: All components of the decision process have been put in place and have collaborated to provide advice to inform policy on provincial health services. Of nineteen technologies selected for review, five have been completed and decisions made: laparoscopic adjustable gastric banding, fetal fibronectin assay for premature labor, newborn screening for cystic fibrosis, newborn screening for inborn errors of metabolism, and gastric electrical stimulation. A further six reviews are in progress, and reviews of the remaining technologies are planned for 2007.Conclusions: Bridging the evidence-to-policy gap is more likely to succeed when the policy community is actively engaged and an explicit model is used to put health technology assessment into practice.


2015 ◽  
Vol 31 (4) ◽  
pp. 223-225 ◽  
Author(s):  
Andrew Dillon

Health systems around the world cope with the challenge of difficult economic times, and the value of health technology assessment (HTA) is increasing. Making the right choices, with limited resources, in the face of increasingly complex technologies requires decisions informed by data and analyses that help us to manage the risks involved. Those who undertake and use HTA can play a greater role in helping decision makers meet these challenges; they need to think how to define innovation and respond to it, how to communicate their analyses, and, critically, how to align their work with the ambitions of their health systems. HTA can become a key health system enabler without compromising its objectivity or independence. It can say that it is too early to determine the value of a new technology when the data simply will not support a safe decision. However, it can also be bold and recommend the managed introduction of new technologies, even when the when the data is immature, provided that the health system understands the risks and there is a plausible case for believing that further research will support the value proposition. The goal for HTA is to be able confidently to do both.


2016 ◽  
Vol 32 (1-2) ◽  
pp. 78-80 ◽  
Author(s):  
Lyazzat Kosherbayeva ◽  
David Hailey ◽  
Kural Kurakbaev ◽  
Aleksey Tsoy ◽  
Ormanbek Zhuzzhanov ◽  
...  

Objectives: The aim of this study was to implement health technology assessment (HA) in the First General City Hospital in Astana, Kazakhstan.Methods: We organized trainings to familiarize hospital staff with the purpose and details of HTA. An HTA committee was established, with representation from hospital physicians and managers, and criteria for prioritization of health technologies determined. Clinical departments of the hospital were asked to prepare applications for new technologies for their services.Results: The HTA committee reviewed five applications and selected a technology from one of these, on single incision laparoscopic surgery (SILS), for assessment. A short HTA report on SILS was prepared, covering its safety, clinical effectiveness, and cost effectiveness. The report was used to support a request to the Department of Health for additional funding to implement this technology within the hospital. This funding was approved and SILS was established in several hospital departments.Conclusions: This successful initial experience with HTA has paved the way for its routine use by the hospital for informing decisions on the procurement and use of new health technologies.


2020 ◽  
Vol 36 (S1) ◽  
pp. 24-24
Author(s):  
Andrey Avdeyev ◽  
Aigul Kaptagayeva ◽  
Valeriy Benberin ◽  
Nasrulla Shanazarov ◽  
Larissa Makalkina ◽  
...  

IntroductionHospital-based health technology assessment (HB-HTA) in Kazakhstan is currently at the initial stage of development. The Medical Center Hospital of the President's Affairs Administration, Nur-Sultan is one of the first examples of implementing and using an HB-HTA system in practice, having included in its structure an HB-HTA unit in 2015.MethodsIn order to evaluate the current situation of using the principles of HB-HTA in Kazakhstan hospitals, a special questionnaire was developed. The questionnaire was sent in the form of an official request on behalf of the Ministry of Health Care. An official response was received from twenty-nine hospitals, of which nine were at the federal level, thirteen at the regional level, and seven at the city level.ResultsOf the twenty-nine hospitals that participated in the survey, only half (52%) indicated that they were aware of the principles of using the HB-HTA system and of the structure and functions of mini-health technology assessment reports (55%). Nonetheless, most hospitals (90%) noted that the results of HB-HTA may affect the final decision on implementing new technologies in practice, and that using the systematic approach of technology assessment is necessary.ConclusionsIn assessing the clinical and economic effectiveness of new health technologies in hospitals, and the viability of implementing them, there is a lack of standardized processes in managerial decision making. The assessment of clinical effectiveness and safety when implementing technologies is carried out mainly by technology applicants or by the main specialists who are responsible for the profile of evaluating technology. This can be regarded as a conflict of interest, since the applicant's wish to introduce the new technology may bias the evaluation process.


2017 ◽  
Vol 33 (S1) ◽  
pp. 62-62 ◽  
Author(s):  
Roberta Rabelo ◽  
Vania Canuto ◽  
Clarice Petramale ◽  
Tacila Mega

INTRODUCTION:Since the creation of the National Committee for Health Technology Incorporation in the Brazilian Health System (CONITEC), a new phase started in the public Brazilian Health System (SUS): a continuous updating of the system based on Health Technology Assessment (HTA). CONITEC was created by federal law in 2012 and is responsible for advising the Ministry of Health regarding the incorporation or disinvestment of health technologies. The whole process involves a strong interaction with society, including the composition of the committee, which has the participation of the National Health Council. The objective of this study was to describe the results of CONITEC in five years of operation.METHODS:This is a retrospective descriptive study, based on information from the database (period 2012–2016) and CONITEC's website.RESULTS:Since 2012, CONITEC assessed 541 technologies, including drugs (360), health products (71) and procedures (110); 303 assessment requests came from SUS agencies and institutions and the other 238 requests from pharmaceutical companies, medical societies, patient associations and the judiciary bodies. In this period, there were 190 public consultations, during which more than 24,000 feedback from society were received. The average time for evaluation was 146 days. The committee recommended the incorporation of 186 technologies into SUS, the disinvestment of 43 and was unfavorable to the incorporation of 88, generating a budgetary impact of approximately BRL2.5 billion (USD764 million).CONCLUSIONS:From 2012–2016, CONITEC tripled the average annual incorporation of new technologies compared to the period 2006–2011. In this process, it was necessary to assess efficacy, safety and cost-effectiveness of technologies, generating positive results for the expansion of access, health gains for patients and sustainability for the system. It should be considered that the use of evidence for decision making strengthens transparency in public management and the development of active processes of information, communication and social participation.


2009 ◽  
Vol 25 (S1) ◽  
pp. 174-177 ◽  
Author(s):  
Pedro Koch ◽  
Julian Schilling ◽  
Marlène Läubli ◽  
Florian Mitscherlich ◽  
Dieter Melchart ◽  
...  

Objectives and Methods: To review Switzerland's mixed public and private healthcare system with regard to health technology assessment (HTA).Results: In the past, remarkable work in HTA was done. Accomplishments include the following: (i) Switzerland became an early member of the International Network of Agencies for Health Technology Assessment. (ii) HTA has its legal bases in terms of effectiveness, appropriateness, and efficiency. (iii) The federal law allows the introduction of new technologies for a limited time for evaluation. (iv) A Swiss Network for Health Technology Assessment was established. In 2004, federal HTA activities moved from the Swiss Federal Office “of Social Security” to the one for “Public Health.” The Office mainly mandates, manages, and coordinates evaluations attached to its prevention and intervention sections in the fields of AIDS, illegal drugs, and legal drugs.Conclusions: Because of the absence of a governmental institution assessing and reporting on new health technologies, private and for profit organizations became more important for the decision-making processes. In a regulated market, the implications may be crucial for the public health.


Sign in / Sign up

Export Citation Format

Share Document